**DELETION OF THE BAFF RECEPTOR TACI FULLY PROTECTS AGAINST SLE WITHOUT REDUCTION OF B CELL NUMBERS AND FUNCTION**

1F Mackay*, 1University of Melbourne, School of Biomedical Sciences, University of Melbourne, Australia

10.1136/lupus-2017-000215.345

**Background and aims** B cell-activating factor of the TNF family (BAFF) is an essential B cell survival factor. However, high levels of BAFF promote systemic lupus erythematosus (SLE) in mice and humans. Belimumab (anti-human BAFF) limits B cell survival and is approved for use in patients with SLE. Surprisingly, the efficacy of rituximab in SLE remains controversial, despite depleting B cells more potently than belimumab. This raises the question of whether B cell depletion is really the mechanism of action of belimumab. In BAFF transgenic (BAFF-Tg) mice, SLE development is T cell-independent but relies on innate activation of B cells in cooperation with the BAFF receptor TACI. Therefore, in this study we tested whether TACI, a BAFF receptor dispensable for B cell survival, is protective in SLE.

**Methods** To test the role of TACI in driving BAFF-mediated autoimmune disease, we reconstituted BAFF Tg mice with a TACI-deficient bone marrow and also crossed BAFF Tg mice onto TACI−/− mice. T cell cross-priming in driving BAFF-mediated autoimmunity, we reconstituted BAFF Tg mice with a TACI-deficient bone marrow and also crossed BAFF Tg mice onto TACI−/− mice. T cell cross-priming in driving BAFF-mediated autoimmunity, we reconstituted BAFF Tg mice with a TACI-deficient bone marrow and also crossed BAFF Tg mice onto TACI−/− mice. T cell cross-priming in driving BAFF-mediated autoimmunity, we reconstituted BAFF Tg mice with a TACI-deficient bone marrow and also crossed BAFF Tg mice onto TACI−/− mice. T cell cross-priming in driving BAFF-mediated autoimmunity, we reconstituted BAFF Tg mice with a TACI-deficient bone marrow and also crossed BAFF Tg mice onto TACI−/− mice.

**Results** We show that loss of TACI on B cells protected against BAFF-mediated autoimmune manifestations while preserving B cells, suggesting that loss of BAFF signalling through TACI, rather than loss of B cells, may underpin the effect of belimumab in the clinic. Moreover, a multimeric form of BAFF, very effective at activating TACI, suggests that this abnormal form of BAFF may also be a pathogenic factor in SLE.

**Conclusions** B cell-sparing blockade of TACI may offer a more specific and safer therapeutic alternative to broad B cell depletion in SLE.

---

**THE CONTRIBUTION OF Interferon Lambda to SLE**

1C Macri*, 1ES Pang, 1Posley, 2K Radford, 1M O’Keeffe. 1Monash University, Biochemistry and Molecular Biology, Clayton, Australia; 2Mater Research-UQ, TRI, Brisbane, Australia

10.1136/lupus-2017-000215.346

**Background and aims** Interferon lambda (IFN-λ) is a novel type of interferon produced by dendritic cells (DC). Despite its binding to a different receptor, IFN-λ shares functional similarities with type I IFN (IFN-I) by upregulating the expression of IFN-stimulated genes. The role of IFN-λ in DC biology and in autoimmunity remains unknown.

- to identify the DC subsets producing IFN-λ.
- to investigate the role of IFN-λ in DC functions.
- to investigate the role of IFN-λ in SLE.

**Methods**

- Mouse and human DC subsets were stimulated ex vivo and the IFN-λ expression was measured.
- The maturation and the capacity of DC to cross-prime T cells was compared in WT and IFN-λ−/− mice. T cell cross-priming by human DCs was measured ex vivo in the presence of exogenous IFN-λ.
- Serum levels of IFN-λ were measured in lupus-prone mice and in SLE patients. The phenotype of the blood DC subsets from SLE patients was also characterised.

**Results**

- Mouse plasmacytoid DC (pDC) and CD8+ DC highly secrete IFN-λ. In humans, the CD141+ DC are the major IFN-λ producers.
- IFN-λ enhances the capacities of mouse and human DCs to mature and to cross-prime T cells.
- High serum levels of IFN-λ were detected in lupus-prone mice and in some SLE patients. SLE patients display increased activation of the IFN-producing DC subsets: the pDCs (producing IFN-I) and the CD141+ DCs (producing IFN-λ).

**Conclusions** IFN-λ is produced by some DC subsets and enhances their functions. Furthermore, IFN-λ is expressed during SLE, suggesting a potential role of the cytokine in the aetiology of SLE.

---

**IMPACT OF CD200-FC ON DENDRITIC CELLS IN LUPUS-PRONE NZB/WF1 MICE**

W Mo*, Y Yin, X Zhang, Beijing peking union medical college hospital, rheumatology, Beijing, China

10.1136/lupus-2017-000215.347

**Background and aims** Abnormal expression of CD200/CD200R1 may contribute to the immunologic abnormalities in patients with systemic lupus erythematosus (SLE). This study aimed to assess the function of CD200/CD200R1 and impact of CD200-Fc on dendritic cells in lupus-prone NZB/WF1 mice.

**Methods** Female NZB/WF1 mice were treated with CD200-Fc or control for 4 weeks. Plasma samples were collected to measure autoantibody levels. The expression levels of CD200/CD200R1 in peripheral blood mononuclear cells (PBMCs) and splenocytes were examined.

**Results** The percentage of CD200/CD200R1-positive cells in splenocytes from NZB/WF1 mice was lower than that of C57BL/6 mice (p<0.05). The plasma level of anti-dsDNA was significantly higher in NZB/WF1 mice than C57BL/6 mice (p<0.001). However, the anti-dsDNA levels decreased (p=0.047) after CD200-Fc treatment. Finally, CD200-Fc reduced the levels of IL-6 (p=0.017) and IL-10 (p=0.03) in the dendritic cell culture supernatant.

**Conclusions** The immunosuppressive CD200/CD200R1 signalling pathway might be involved in the immunopathology of NZB/WF1 mice; the present results merit further exploration of agents that can modulate the CD200/CD200FR1 pathway as a therapy for human lupus.

---

**DECTIN-1 ON MONOCYTIC CELLS MEDIATES ABERRANT INNATE AND ADAPTIVE IMMUNE RESPONSES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS**

1MY Mok*, KY Lam, D Luk, Y Lo. 1City University of Hong Kong, Department of Biomedical Sciences, Hong Kong, Hong Kong S.A.R; 2University of Hong Kong, Department of Medicine, Hong Kong, Hong Kong S.A.R

10.1136/lupus-2017-000215.348